GLYC 1.99 - traded it a couple times recently for a few pennies, several irons in the fire, and remains high on my biobust watchlist.
"There are now six trials underway evaluating our lead clinical candidate, uproleselan, including three registration trials and three ISTs, which we anticipate will provide clinical data flow beginning in 2022.
A few months ago, I'd have been way more aggressive at this pps in GLYC, but I'm convinced the indexes are waaaayyyyyy too high. And it's even probable that the robinhooligans will be just as overeager in their eventual selling as they've shown to be in their overeager buying???
Market Data 
Markets 
AI
